Found: 12
Select item for more details and to access through your institution.
A 3D Model of Human Buccal Mucosa for Compatibility Testing of Mouth Rinsing Solutions.
- Published in:
- Pharmaceutics, 2023, v. 15, n. 3, p. 721, doi. 10.3390/pharmaceutics15030721
- By:
- Publication type:
- Article
Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy.
- Published in:
- Cancers, 2023, v. 15, n. 13, p. 3364, doi. 10.3390/cancers15133364
- By:
- Publication type:
- Article
Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.
- Published in:
- Cancers, 2023, v. 15, n. 13, p. 3317, doi. 10.3390/cancers15133317
- By:
- Publication type:
- Article
Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models.
- Published in:
- Cancers, 2023, v. 15, n. 3, p. 904, doi. 10.3390/cancers15030904
- By:
- Publication type:
- Article
Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments.
- Published in:
- Cancers, 2022, v. 14, n. 23, p. 5802, doi. 10.3390/cancers14235802
- By:
- Publication type:
- Article
The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD 2 Antibody Dinutuximab Beta.
- Published in:
- Cancers, 2022, v. 14, n. 19, p. 4842, doi. 10.3390/cancers14194842
- By:
- Publication type:
- Article
Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.
- Published in:
- Cancers, 2018, v. 10, n. 10, p. 387, doi. 10.3390/cancers10100387
- By:
- Publication type:
- Article
Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.690467
- By:
- Publication type:
- Article
Generation and Characterization of a Human/Mouse Chimeric GD<sub>2</sub>-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.
- Published in:
- PLoS ONE, 2016, v. 11, n. 3, p. 1, doi. 10.1371/journal.pone.0150479
- By:
- Publication type:
- Article
Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study.
- Published in:
- British Journal of Cancer, 2023, v. 129, n. 11, p. 1780, doi. 10.1038/s41416-023-02457-x
- By:
- Publication type:
- Article
GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma.
- Published in:
- Journal of Neuro-Oncology, 2020, v. 147, n. 3, p. 577, doi. 10.1007/s11060-020-03470-3
- By:
- Publication type:
- Article
Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice.
- Published in:
- PLoS ONE, 2018, v. 13, n. 11, p. 1, doi. 10.1371/journal.pone.0207320
- By:
- Publication type:
- Article